Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study

Authors:

Abstract
1. The transition from intravenous (IV) to subcutaneous (SC) delivery of biotherapeutics, such as monoclonal antibodies (mAbs), is prominent for a variety of reasons. Perhaps the most important is ...
Funding Information
  • Matchstick LLC
  • AstraZeneca

This publication has 135 references indexed in Scilit: